Last reviewed · How we verify
NCT06820515
ATHNdataset Registry
trial in Hemophilia in 200,000 participants. Enrolling by invitation.
25 October 2054
Quick facts
| Lead sponsor | American Thrombosis and Hemostasis Network |
|---|---|
| Status | ENROLLING BY INVITATION |
| Study type | OBSERVATIONAL |
| Enrollment | 200,000 |
| Start date | 25 October 2024 |
| Primary completion | 25 October 2054 |
| Estimated completion | 31 October 2055 |
| Sites | 1 location across United States |
Conditions studied
- Hemophilia — all drugs for Hemophilia →
- Thrombosis — all drugs for Thrombosis →
- Hemophilia A — all drugs for Hemophilia A →
- Hemophilia B — all drugs for Hemophilia B →
Sponsor
American Thrombosis and Hemostasis Network
Who can join
Eligibility, any sex, with Hemophilia or Thrombosis. Patients with the condition only — healthy volunteers not accepted.
Sponsor's own description
The Hemophilia Treatment Center (HTC) where you receive care is working with The American Thrombosis and Hemostasis Network (ATHN) to look at the quality of life of people with blood disorders and problems. Doctors, scientists, policymakers, and other health care providers need a large amount of information from a lot of people to answer scientific, public health, and policy questions about better ways to treat blood disorders. They will use the information from the ATHNdataset to answer these questions.
Publications & conference data
No peer-reviewed publications indexed yet for this trial.
Verify or expand the search:
- PubMed search for NCT06820515
- Europe PMC full search
- ASCO Meeting Library
- ESMO Meeting Library
- bioRxiv preprints
- medRxiv preprints
- Google Scholar
Related trials
Other recruiting trials for Hemophilia
Currently open trials in the same condition.
- NCT07579585 — Effects of Photobiomodulation in Hemophilia Patients. · NA · recruiting
- NCT07406139 — PCC Treatment for Hemophilia Patients With Inhibitor（2022PCC-A） · Phase 4 · recruiting
- NCT07285460 — A Study to Investigate the Efficacy and Safety of Fitusiran Prophylaxis in Male Participants Aged 1 to Less Than 12 Year · Phase 3 · recruiting
- NCT07187661 — Intra-Articular Bevacizumab for Preventing Recurrent Hemarthrosis in Hemophilia With Chronic Synovitis · NA · recruiting
- NCT07099313 — Association of Prophylactic Treatment With Treatment Burden and Psychosocial Variables in Patients With Hemophilia · recruiting
Other American Thrombosis and Hemostasis Network trials
Trials by the same sponsor.
- NCT04647227 — SEVENFACT® for Bleeding Events in Hemophilia With Inhibitors · Phase 4 · recruiting
- NCT04055051 — ATHN 11: Liver Transplantation Outcomes Study · completed
- NCT03853486 — ATHN 9: Severe VWD Natural History Study · active not recruiting
- NCT03619863 — ATHN 7: Hemophilia Natural History Study · completed
- NCT03818529 — ATHN 8: Previously Untreated Patients (PUPs) Matter Study · completed
Verify against primary sources
- ClinicalTrials.gov — authoritative US registry record
- WHO ICTRP — international registry index
- EU Clinical Trials Register
- Sponsor press releases (Google)
- Trial protocol + status: ClinicalTrials.gov NCT06820515 (US National Library of Medicine, public domain)
- Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
- Sponsor: as reported to ClinicalTrials.gov by American Thrombosis and Hemostasis Network
- Last refreshed: 1 April 2025
Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT06820515.
Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing